Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs State Street Technology Select Sector SPDR ETF — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while State Street Technology Select Sector SPDR ETF trades at $188.13 (market cap $129.38B). The key difference: State Street Technology Select Sector SPDR ETF is far larger — about 133× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and State Street Technology Select Sector SPDR ETF for 50 Days on average.
| MRVI | XLK | |
|---|---|---|
Market Cap | $972.90M | $129.38B |
Volume | 4,325,710 | 6,753,008 |
Sector | Health | Sector/Thematic |
52-Week High | $9.00 | $202.00 |
52-Week Low | $2.83 | $127.49 |
Typical Hold Time | 0 Days | 50 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
XLK trades at $196.24, down slightly by 0.06% on the day, with a bullish technical signal from moving averages while oscillators remain neutral. The ETF faces concentration concerns despite its tech sector exposure, with recent news highlighting AI-driven opportunities and potential interest rate impacts. Support levels are established at $195 and $194, with resistance at $198 and $199.
The outlook for XLK remains positive given strong AI investment themes and large-cap tech resilience, though risks include Fed rate hike sensitivity and sector concentration. Investor sentiment is mixed, balancing growth potential against macroeconomic headwinds and valuation pressures in the technology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
